

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

15. (New) A process for providing a human with a therapeutic protein comprising: introducing autologous human cells into a human, said autologous human cells having been treated *in vitro* to insert therein a DNA segment encoding a therapeutic protein, said autologous human cells expressing *in vivo* in said human a therapeutically effective amount of said therapeutic protein, wherein said therapeutic protein is a cytokine other than TNF.
16. (New) The process of claim 15, wherein the cells are blood cells.
17. (New) The process of claim 16, wherein the cells are leukocytes.
18. (New) The process of claim 16, wherein the cells are lymphocytes.
19. (New) The process of claim 18, wherein the cells are T-lymphocytes.
20. (New) The process of claim 19, wherein said cells are tumor infiltrating lymphocytes (TIL).
21. (New) The process of claim 18, wherein the cells are B-lymphocytes.
22. (New) The process of claim 15, wherein the cytokine is an interleukin.
23. Canceled.
24. (New) The process of claim 15, wherein the cytokine is an interferon.
25. (New) The process of claim 15-22, and 24 wherein said DNA segment has been inserted into said cells *in vitro* by a viral vector.

26. (New) The process of claim 25, wherein said viral vector is a retroviral vector.
27. (New) A process for providing a human with a therapeutic protein comprising: introducing autologous human B-lymphocytes into a human, said autologous human B-lymphocytes having been treated *in vitro* to insert therein a DNA segment encoding a therapeutic protein, said autologous human B-lymphocytes expressing *in vivo* in said human a therapeutically effective amount of said therapeutic protein.
28. (New) The process of claim 27, wherein the DNA segment has been inserted into the cells *in vitro* by a viral vector.
29. (New) The process of claim 28, wherein the viral vector is a retroviral vector.
30. (New) The process of claim 22, wherein the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, and IL-12.
31. (New) The process of claim 30, wherein the interleukin is IL-2.
32. (New) The process of claim 24, wherein the interferon is selected from the group consisting of IFN- α , IFN- β , and IFN- γ .
33. (New) The process of claim 32, wherein the interferon is IFN- γ .